OTCBB:CNBX

Cannabics Pharma Stock News

Healthcare > Biotechnology

Buy CNBX

*Your capital is at risk

$0.0002

+0 (+0%)

At Close: Jun 03, 2026

The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company's Personalized Medicine Drug Discovery Technology

08:45am, Tuesday, 25'th May 2021

TEL AVIV, Israel and BETHESDA, Md., May 25, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, annou

Cannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations

08:45am, Tuesday, 11'th May 2021

TEL AVIV, Israel and BETHESDA, Md., May 11, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, annou

Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

09:18am, Tuesday, 16'th Feb 2021

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 16, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, ha

Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

09:20am, Wednesday, 03'rd Feb 2021

TEL AVIV, Israel and BETHESDA, Maryland, Feb. 3, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, an

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by